Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Advances in non-covalent BTK inhibitors for CLL: BRUIN study update

Krish Patel • 7 Sep 2023
SOHO 2023
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Pirtobrutinib
BRUIN

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, comments on recent advances with the use of non-covalent BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia (CLL), highlighting long-term follow-up data from the Phase I/II BRUIN study (NCT03740529). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals